ArriVent BioPharma, Inc. Common Stock Cash Flow-to-Debt Ratio
ArriVent BioPharma, Inc. Common Stock cash flow-to-debt ratio. ArriVent BioPharma, Inc. Common Stock (AVBP) has a Cash Flow-to-Debt Ratio of -1.42x as of June 2026, meaning its operating cash flow of $-39.58 Million could theoretically repay -1% of its total liabilities ($27.88 Million) in one year. See ArriVent BioPharma, Inc. Common Stock financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ArriVent BioPharma, Inc. Common Stock (2021–2025)
Cash flow-to-debt ratio of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. Historical debt coverage capacity for ArriVent BioPharma, Inc. Common Stock across 5 annual periods. Also explore ArriVent BioPharma, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
ArriVent BioPharma, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2021–2025)
ArriVent BioPharma, Inc. Common Stock cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for ArriVent BioPharma, Inc. Common Stock. For the full cash flow conversion analysis, see AVBP operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | $-160.59 Million | $25.95 Million | ▼ -52.4% |
| 2024 | -4.06x | $-70.21 Million | $17.29 Million | ▲ +14.2% |
| 2023 | -4.73x | $-55.84 Million | $11.80 Million | ▲ +9.2% |
| 2022 | -5.21x | $-43.63 Million | $8.37 Million | ▲ +24.7% |
| 2021 | -6.92x | $-12.59 Million | $1.82 Million | — |